Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S, López B, Ferreira JP, Girerd N, Bozec E, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Moreno MU, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Cleland JGF, Zannad F, Díez J, González A; HOMAGE Trial Committees and Investigators.
Ravassa S, et al. Among authors: clark al.
Eur J Heart Fail. 2022 Feb;24(2):321-331. doi: 10.1002/ejhf.2394. Epub 2021 Dec 9.
Eur J Heart Fail. 2022.
PMID: 34841615
Free article.
Clinical Trial.